Patient Background:

Mr. C is a 52-year-old male with a BMI of 37 kg/m² and a 10-year history of obesity with multiple prior attempts at sustained weight loss through calorie restriction and exercise.

Comorbidities include hypertension (amlodipine 10 mg), dyslipidemia (atorvastatin 40 mg), prediabetes (HbA1c 6.2%), and obstructive sleep apnea managed with CPAP. He is a non-smoker. Family history includes paternal myocardial infarction at age 58. He is motivated for pharmacologic intervention and has enrolled in a structured lifestyle program.

Assessment & Diagnosis:

Waist circumference: 116 cm. BP: 138/86 mmHg. Fasting glucose: 108 mg/dL. LDL-C: 118 mg/dL.…read more

1. Please provide a minimum of a 3 sentence response.
2. 1.Which comorbidities support GLP-1 RA therapy in this patient?
3. 2.What counseling strategies help minimize GI adverse effects during GLP-1 RA dose escalation?

Show Less

Erik Nelson, PhD, Professor at the University of Illinois Urbana-Champaign and Basic Science Chair for ENDO 2026, highlighted research involving cholesterol regulation and the evolution of GLP-1/GIP agonist therapies for diabetes and obesity. He also discussed their reported cardiovascular benefits and other areas of ongoing investigation. Micah Eimer, MD, General Cardiologist at Northwestern Medicine in Chicago, presented a study examining hypotension among patients who initiated GLP-1–based therapy while taking antihypertensive medications. His observations highlight the importance of monitoring low blood pressure, falls, and fainting in this clinical setting.

As obesity care continues to evolve, clinical focus is shifting from initiating therapy to managing obesity as a long-term, relapsing condition. Recent advances in oral glucagon-like peptide-1 (GLP-1) receptor agonist development reinforce this shift, prompting clinicians to consider not only whether to use pharmacologic therapy, but how it can be integrated into sustained, multidimensional care plans over time.

GLP-1 receptor activation influences appetite regulation, satiety signaling, and metabolic pathways central to obesity pathophysiology. Oral formulations demonstrate that these mechanisms can be engaged through daily administration, expanding how clinicians think about treatment design and long-term engagement. This evolution brings renewed attention to clinical integration—how pharmacologic therapy aligns with behavioral strategies, lifestyle interventions, and ongoing monitoring rather than functioning as a stand-alone solution.

Patient selection and adherence remain central considerations in long-term obesity management. Functional factors such as daily dosing routines, gastrointestinal tolerability, and treatment fatigue—as well as emotional factors including expectations, motivation, and prior weight-loss experiences—may influence sustained use and outcomes. These considerations highlight the importance of shared decision-making and regular reassessment as patient needs and priorities evolve.

Rather than viewing therapy choice as a single decision point, many clinicians are approaching obesity care as a dynamic process that requires adjustment over time. Evidence-based strategies increasingly emphasize structured follow-up, realistic goal-setting, behavioral support, and coordinated, multidisciplinary care. Within this framework, oral GLP-1 approaches may offer flexibility across different phases of treatment, including escalation, stabilization, or maintenance.

What factors most influence how you select patients for long-term pharmacologic obesity therapy?As oral GLP-1 options enter clinical practice, what adherence challenges or integration considerations will most shape how you incorporate them into comprehensive obesity care?